Long-term therapy with protease inhibitors (PIs) can induce hypertriglyceridemia and development of a lipodystrophy. To better understand these metabolic alterations, the apoprotein and lipoparticle profile was investigated in male HIV patients under antiretroviral therapy: 49 received PIs, and 14 were given only two reverse transcriptase inhibitors. As controls, 63 male subjects were selected from a population study carried out in the Toulouse, France, area. Fasting glucose, insulin, and C-peptide were also determined. All patients under PIs displayed low levels of plasma glucose and increased insulin. PI administration was associated with moderate hypertriglyceridemia, low high-density cholesterol and apolipoprotein (apo) A-I levels. The most striking changes were a 2-to 3-fold increase in apo E and apo C-III, essentially recovered as associated to apo B-containing lipoparticles. Levels of those lipoparticles were two to eight times above control values. About 50% of PI-treated patients had developed a patent lipodystrophy. Multivariate analysis revealed that, among the investigated parameters, apo C-III was the only one found strongly associated with the occurrence of lipodystrophy (odds ratio, 5.5; P Ͻ 0.015). Finally, 13 PI-receiving subjects with patent hypertriglyceridemia were given fenofibrate and were reevaluated 2 months later. Triglycerides, apo E, apo C-III, and the corresponding lipoparticles had returned to nearly normal levels. These results document the accumulation of potentially atherogenic lipoparticles under PIs. Apo C-III may play a pivotal role in the development of hypertriglyceridemia and lipodystrophy. (J Clin Endocrinol Metab 86: 296 -302, 2001) 
T HE WIDESPREAD USE of protease inhibitors (PIs) as antiretroviral therapy, and their long-term administration, has revealed secondary metabolic adverse effects. Dyslipemia, including hypertriglyceridemia or combined hyperlipemia, has been repeatedly reported, as well as glucose intolerance and hyperinsulinism (1) (2) (3) (4) . The mechanisms behind those metabolic alterations are not fully understood and are actively debated. Nevertheless, these metabolic troubles may constitute risk factors for atherosclerosis and coronary artery disease (3) .
In most reports, the dyslipemia associated with antiretroviral therapy has been assessed from measurements of lipids, cholesterol distribution, and of major apolipoproteins (apos) (3, 4) . However, lipoproteins are heterogeneous in terms of apoprotein composition, enabling to define subclasses of lipoparticles, which differ in their pro-(or anti-) atherogenic potential (5) . In front of a mild hyperlipemia, identification of the accumulating lipoparticles is helpful to precise the atherogenicity of the lipoprotein profile. For instance, increased levels of complex lipoparticles, containing apo C-III and/or apo E, and apo B have been found in coronary artery disease patients (6, 7) . Several factors may contribute to the pathogenesis of hypertriglyceridemia, like an increased synthesis of triglycerides (TGs) and very low-density lipoproteins (VLDLs), a lipolysis defect, or an impaired hepatic clearance of remnant lipoproteins derived from VLDLs or chylomicrons. Apo C-III seems to be a key protein modulating both the synthesis and catabolism of VLDLs (8, 9) . On the other hand, apo E plays a major role in the catabolism of remnant lipoproteins, being a high-affinity ligand for hepatic receptors (10) . Thus, a precise characterization of the accumulating lipoparticles should help to identify the mechanisms underlying the development of dylipidemia.
Occurrence of a lipodystrophy (LD) has also been commonly described on antiretroviral treatment, the most frequent aspect associating a wastage of the face and limbs, and an increase in abdominal fat (1, 11, 12) . Despite the elevated prevalence of this LD (between 30% and 70% among studies), the factors or metabolic indices associated with its development have not been clearly elucidated.
The present study demonstrates that the moderate hypertriglyceridemia observed on PIs is associated with marked increases in complex lipoparticles containing apo B associated with apo C-III and/or apo E and points out apo C-III as an important determinant of the associated LD.
were included. Seventy-eight patients, among them 63 males, were found eligible according to inclusion/exclusion criteria. Informed consent was obtained from each participant. Among male patients, 49 were under tri-or quadri-therapy including PIs, whereas 14 others received only two reverse transcriptase nucleosidic inhibitors (RTNIs). Patients were excluded from the study under the following circumstances: age under 18 yr, presence of a diabetes, obesity with a body mass index (BMI) of 27 kg/m 2 or more, patent hyperlipemia before setting up the antiviral therapy (cholesterol Ն6.8 mmol/L and/or TGs Ն2.3 mmol/L), a known endocrinopathy (dysthyroidia, hypercorticism, etc.), hepatic failure, presence at the time of the examination of an opportunistic infection, and, for PI-treated patients, less than 4 months of PI administration. Distribution of the patients among the different clinical stages (A, B, and C) of the infectious disease was assessed according to the classification of the Centers for Diseases Control (1993) (13) . Stage A includes asymptomatic patients and those with a persistent generalized lymphoadenopathy. Stage B includes minor opportunistic infections (essentially, oral candidiasis, oral hairy leukoplakia, Herpes zoster infection, and peripheral neuropathy). Stage C includes major opportunistic infections (among our patients: esophageal candidiasis, extrapulmonary cryptococcosis, cytomegalovirus retinitis, recurrent Herpes simplex infection, HIV-associated dementia, Kaposi's sarcoma, non-Hodgkin's lymphoma, Mycobacterium avium infection, Mycobacterium tuberculosis, Pneumocystis carinii, and brain toxoplasmosis).
Bioclinical examinations included routine determinations of the viral load, total blood cell and CD4 lymphocytes counts, the electrolytic balance, and liver enzyme activities. Besides, a complete evaluation of the lipoprotein profile was performed, and parameters of glucose homeostasis were measured.
Among PI-treated patients, some of them presented a LD, as clinically assessed by at least two of the following criteria: leaning with wasting of sc adipose tissue on the face, upper and lower limbs, and buttocks. These signs had to be associated with an increase in abdominal obesity in males, and in women, with an enhanced breast volume. Fat accumulation in the dorso-cervical area (buffalo-humps), as reported elsewhere (14) , was never observed in our patients. The clinical criteria for LD were confirmed by dual-energy x-ray absorptiometry (DEXA) (15) , enabling to determine body composition and fat distribution. LD was characterized by a low ratio of lower limb fat/total body fat and a high ratio of abdominal visceral fat/total body fat, by comparison with reference values obtained from age-and gender-matched individuals.
To get control reference values for all investigated parameters, 63 male subjects, living in the same geographical area, were selected so as to be matched for age with the PI-treated patients. Those subjects were recruited in a population study carried out in the frame of the MONICA center. The MONICA project is a WHO-supported multinational collaborative program, surveying the level and evolution of cardiovascular disease risk factors in 38 reference centers in 28 different countries (16) , and one of these centers is located in Toulouse. Among their activities, the French MONICA centers periodically realize population studies, including questionnaires, clinical examination, and biological measurements. The recruitment is a random sampling representative of the regional population, based on polling lists.
Analytical methods
Blood samples were taken after a minimum 10-h fast. CD4 cell counts were determined by flow cytometry. The viral load in plasma was measured by quantitative PCR and is expressed as number of HIV-RNA copies per milliliter (17) . Plasma glucose, TGs, and total cholesterol were measured with enzymatic reagents on an automated analyzer (DadeBehring, Les Ulis, France), as described in Ref. 18 . High-density lipoprotein cholesterol (HDL-cholesterol) was assayed following a prior precipitation of apo B/apo E-containing lipoproteins with phosphotungstic acid and magnesium (Roche-Diagnostics, Meylan, France). Low-density lipoprotein cholesterol (LDL-cholesterol) was calculated according to Planella et al. (19) , because this equation integrates, for a large part, the apo B value and is more appropriate in case of significant hypertriglyceridemia. Apo A-I, apo B100, and lipoprotein (a) [Lp(a)] were determined by first order immunoprecipitation in an automated analyzer (Cobas-Mira; Roche-Diagnostics). Total apo C-III and the apo C-III associated with apo B-containing particles (Lipo B:C-III) were measured by electroimmunoassay combined with an immunoprecipitation of apo B-containing lipoproteins (Sebia, Issy-les-Moulineaux, France) (5). Similar techniques were used for the determination of total apo E and of the apo E associated with apo B-containing particles (Lipo B:E), and for Lipo A-I. Insulin, proinsulin, and C-peptide were measured with specific RIAs (bi-Insuline, RIA-Diagnostics Pasteur, Paris, France; Proinsulin and C-peptide-CTK, DiaSorin, Inc., Anthony, France). The intra-and interassay coefficients of variation for cholesterol, HDL-cholesterol, glucose, apo A-I, and apo B were less than 4%. It was less than 10% in the case of insulin, proinsulin, C-peptide, and lipoparticles measurements.
Statistical analysis
The statistical significance of the differences between groups were analyzed using the 2 test for categorical variables and one-way ANOVA for continuous ones. An analysis of covariance was performed to compare mean values of plasma concentrations of lipids, apos, and lipoparticles after adjustment for confounding factors such as age, BMI, and, when stated, duration of RTNI treatment. Post hoc tests were done when the overall test was significant (P Ͻ 0.05). The Scheffé test was performed after ANOVA and analysis of covariance. Comparisons between before/ after fenofibrate treatment or before/after PI introduction were performed using a paired comparisons Student's t test. For variables with a skewed distribution, analysis was performed after logarithmic transformation. When a close-to-normal distribution was not reached, a Kruskal-Wallis test was used. Stepwise logistic regressions were performed to identify among PI-treated patients, the clinical and biological parameters associated with the occurrence of LD. Each parameter was considered at two levels (i.e. below and above its median value), as determined in our whole population of patients. Time of antiretroviral treatment was forced in the model because it has been identified as a strong determinant of LD onset in several studies (20) . Analysis of maximum likelihood estimates was performed, and odds ratios were determined. Statistical analysis was conducted using the SAS statistical software release 6.12 (SAS Institute, Inc., Cary, NC).
Results

Clinical characteristics and glucose balance
Subsequent patients attending the HIV follow-up consultation were recruited during a 3-month period. Because the metabolic parameters investigated here are highly dependent on gender, only male patients will be further considered. Among them, 14 were treated only with two RTNIs, whereas another 49 also received one (or two) PIs. Regarding RTNI, 70% of patients received Stavudine plus Lamivudine, whereas Didanosine, Zalcitabine, and Zidovudine were given more occasionally. With respect to PIs, most patients were given a single molecule (indinavir, Ritonavir, nelfinavir, saquinavir) and 10 (of 49) received Ritonavir ϩ saquinavir in association.
Distribution of the patients among the clinical AIDS stages was: in the PI group, 41% were at stage A, 25% at stage B, and 34% at stage C; for patients maintained on dual therapy only, 90% were at stage A. To get reference values for all investigated parameters, a sample of 63 male subjects, paired for age with PI-treated patients, was selected from a population study carried out in the same regional area.
Patients treated with RTNI only were younger than in the two other populations (35.8 vs. 42.0 yr; see Table 1 ). Weight and BMI were significantly lower in PI-treated patients than in the other two populations. The total duration of RTNI administration was longest in the patients receiving PI also, because introduction of the latter had generally followed a period of treatment with RTNI only.
The viral load was comparable between the two groups of treated HIV patients, whereas the lymphocyte counts were found 10% higher in PI-treated subjects. Those results indicate a comparable control of the viral infection in both groups.
Regarding glucose homeostasis, levels of glycated hemoglobin were found in the normal range (4 -8%) in all patients. Fasting glucose was lower in all treated HIV patients (4.45 and 4.60 mmol/L) compared with controls (5.60 mmol/L, P Ͻ 0.001), whereas insulin was significantly higher (15.0 mUI/L vs. 9.8 mUI/L, P Ͻ 0.001). The homeostasis model assessment index for insulin resistance (HOMA-IR) was not significantly different between groups (data not shown). However, the HOMA index indicative of ␤-cell function was three times higher in patients than in controls (P Ͻ 0.001). Finally, plasma C-peptide was 50% higher in PI-treated than in PI-naive patients (P Ͻ 0.05). Table 2 displays the crude values for lipoprotein markers, as measured in our three populations. Because the three groups were somewhat different in terms of age and BMI, the statistical significance of differences was assessed after adjustment on age and BMI. Actually, those adjusted values (data not shown) were very close to nonadjusted ones. Regarding apos, both the total measurements and the amounts specifically associated with a definite particle were determined: the Lipo B:C-III and Lipo B:E particles contain apos C-III and E, respectively, associated with apo B, whereas Lipo A-I refers to particles containing apo A-I but no apo A-II.
Lipids, apos, and lipoparticles
Different patterns are seen in Table 2 . TGs, apo C-III, and Lipo B:C-III were 60 -100% higher in PI-treated patients than in PI-naive patients and in control subjects. By contrast, total and LDL-cholesterol, as well as apo B, were significantly lower in RTNI only-treated patients than in the two other groups. The levels of those markers were not different between PI-receiving patients and controls. HDL-cholesterol and apo A-I, parameters of the reverse cholesterol transport, followed a decreasing gradient from controls to PI-naive and then to PI-treated patients, although the intergroup differences did not always reach significance. On the opposite, apo E and Lipo B:E particles displayed a positive gradient: apo E was 80% and 200% increased in RTNI only-and in PItreated patients, respectively, compared with controls. Fourteen male patients treated with two reverse transcriptase inhibitors, and 49 counterparts receiving also at least one PI, were consecutively recruited. Sixty-three control subjects, randomly selected in a population study, were also selected. Data are means and SE. Statistical significance was assessed by the one-way ANOVA test, and pairwise comparisons were performed using the Scheffe's test. Comparisons between groups.
a , P Ͻ 0.01,
b
, P Ͻ 0.001; c , P Ͻ 0.05; when unstated: nonsignificant.
Because the time of exposure to RTNI was clearly different between the two groups of treated patients (42.6 vs. 21.9 months; see Table 1 ), the comparisons between groups 1 and 2 were repeated on values adjusted for age, BMI, and RTNI treatment time (data not shown). Again, the values differed little from those presented in Table 2 . The most important changes concerned HDL-cholesterol and apo A-I, which were no longer significantly different between both groups.
Some biological parameters were routinely measured just before setting up PIs in the regimen. The comparisons for glucose, cholesterol, and TGs before and after PI treatment are shown in Table 3 . The pre-PI values were rather close to those measured in the RTNI only group (compare with Tables 1 and 2). After an average 17-month PI administration, very significant rises in TGs and cholesterol were recorded while glucose levels were unchanged.
Considering the whole population of our treated HIV patients, the median values for all parameters were determined. Those medians coincided rather well with the "classical limits" of normal ranges. Then, the distribution of patients according to those medians was compared between the two groups ( Table 4) . Regarding apo B, TGs, apo E, and apo C-III, the proportions of patients above median values were three times higher among PI-treated than among PI-naive patients. Similar differences were seen for increased levels of Lipo B:E and Lipo B:C-III (data not shown). By contrast, the percentages of subjects with low HDL-cholesterol or elevated Lp(a) (data not shown) were not different between the two groups.
Slight and nonstatistically significant differences were observed in the lipoprotein parameters with respect to the different PIs administered. The highest levels were recorded on Ritonavir (TG, 2.74 Ϯ 0.52 mmol/L; apo C-III, 36.1 Ϯ 6.1 mg/L), and the most moderate levels with indinavir (TG, 2.37 Ϯ 0.45 mmol/L; apo C-III, 31.4 Ϯ 2.4 mg/L). These subgroups were not different with regard to age, BMI, or treatment time.
Associated LD
Among the PI-treated patients, 23 of 49 (47%) had developed a LDϩ, as clinically assessed. LD was confirmed by DEXA. No case of LD was recorded in the RTNI only group. The prevalence of LD was compared according to the median values for the different investigated parameters, as defined above (Table 5 ). Occurrence of LD was 2.5-fold more frequent in patients showing elevated levels of apo B (P ϭ 0.01) or apo C-III (P ϭ 0.002), and a trend to a positive association was also observed for total cholesterol. By contrast, the prevalence of LD was not found associated with levels of any other of the following parameters: HDL-cholesterol, apoprotein A-I, apoprotein E, Lp(a), glucose, and insulin. As well, no association was found between occurrence of LD and age, BMI, the viral load, or the duration of PI administration. Finally, there was a (nonsignificant) tendency toward higher prevalence of LD for longer times of RTNI treatment.
Finally, multiple logistic regressions were performed, considering, for each parameter, the threshold of median values. The duration of RTNI treatment was entered in the model, because several studies have suggested that the risk of LD occurrence would increase with time of exposure to antiretroviral therapy (20) . The multivariate analysis showed that among all parameters, only apo C-III was found highly associated with LD (odds ratio, 5.47; confidence interval, 1.4 -21.6; P ϭ 0.015). There was also a trend to a positive association with apo B, which did not reach statistical significance (odds ratio, 3.66; P ϭ 0.07). No significant association was found with the duration of RTNI treatment (odds ratio, 2.7; P ϭ 0.16).
Effectiveness of fenofibrate in reversing the lipoprotein alterations
As the abnormalities recorded on long-term PI therapy mostly concerned the metabolism of TGs, 13 patients with severe hypertriglyceridemia were consecutively given a fibric acid derivative (fenofibrate, 200 mg/day), and lipoproteins were reevaluated 2 months later (Table 6 ). Patients were not advised to change their dietary habits during this period. Fenofibrate had marked effects on plasma TGs (Ϫ40%), apo E (Ϫ40%), and Lipo B:E (Ϫ50%; data not shown) and modestly on cholesterol, apo B, apo CIII (Ϫ20%), and Lipo B:C-III (Ϫ20%; data not shown). Levels of Lp(a) and of insulin were unmodified after fibrate administration.
Discussion
The present study documents a particular profile of lipoparticles in HIV-infected patients receiving long-term treatment with antiproteases. A moderate hypertriglyceridemia was found associated with marked increases in complex lipoparticles, containing apo B with apo C-III and apo E: Lipo B:E were three times higher than in PI-naive subjects and about 8-fold above controls; Lipo B:C-III levels followed the same rise, although with a lesser magnitude (ϫ2). Those lipoparticles contribute to define an atherogenic lipoprotein profile in PI-treated patients. Among the investigated parameters, elevated apo B and apo C-III were more frequently found in lipodystrophic patients. Moreover, multivariate Plasma glucose, cholesterol, and TGs were determined in group 1 patients, at the time of introduction of PI in the regimen and after long-term PI administration. Statistical comparisons between "after" and "before" PI were assessed by the Student's t test for paired assays.
a , P Ͻ 0.001; 
The comparisons of percentages between the two patients' groups were assessed by the 2 test.
analysis singled out apo C-III as significantly associated with the occurrence of LD. Although hypertriglyceridemia and LD have been repeatedly observed in patients under intensive antiretroviral therapy, the precise role of PI is still actively debated. Different reports suggest that the duration of exposure to treatments, and particularly RTNI, is a strong predictor of the metabolic abnormalities (20) . In the present study, several arguments are in favor of the implication of PI: 1) differences between PI-treated and PI-naive patients persisted after an adjustment on treatment time; 2) cholesterol and TGs were significantly increased after the introduction of PI, in agreement with other studies (21); and 3) in our series, 50% of PI-treated patients presented with a LD vs. none in PI-naive subjects. Recent reports also confirm the role of PI: in the follow-up of almost 3200 patients under highly active antiretroviral therapy-the French Aquitaine Cohort-multivariate analysis demonstrated that PIs are a major contributor for increased TG levels (22) .
Apo C-III seems to be a key apopoprotein regulating both the synthesis and catabolism of TG-rich lipoproteins and of their remnants formed through action of lipoprotein lipase. In transgenic mice, an overexpression of human apo C-III of only 40%, above endogenous levels, was associated with a 3-fold increase in plasma TG (9) . Apo C-III inhibits the apo C-II-activated lipoprotein lipase (23) . Besides, apo C-III impairs the interactions of the neighbor apo E with the LDL receptor or with the LDL receptor-related protein (LRP), a receptor involved in the liver uptake of remnant particles (24) . It has also been demonstrated that the presence of apo C-III on a lipoprotein particle decreases the affinity of the neighbor apo B toward receptors (25) . As a matter of fact, apo C-III impairs the in vivo hepatic uptake of remnant particles (26) . With respect to the lipid-associated vascular risk, Lipo B:C-III would represent cholesterol-enriched remnant particles, potentially atherogenic and associated with the formation of small and dense LDL (27) . In several interventional trials, documented by coronary angiography, the Lipo B:C-III particles were related to the progression of the atherosclerotic lesions (28, 29) .
Apo C-III synthesis is transcriptionally regulated by several mediators (30) . It is down-regulated by insulin (31) and by the ␣ peroxisome proliferator-activated receptor (PPAR␣), a nuclear receptor with multiple target genes involved in lipid metabolism and fatty acid oxidation (32) . The insulin-responsive element and the PPAR recognition element are both located in the proximal (Ϫ500 bp) promoter of the apo C-III gene (30) . Functionally, PPAR␣ heterodimerize with the nuclear retinoic acid receptors, called RXRs (32). Carr et al. (33) have proposed that PIs would impair the activation of the PPAR␣/RXR heterodimer. This hypothesis is based on the homology between the HIV-1 protease and CRABP, a binding protein involved in the cytoplasmic transport of retinoic acid to the mitochondria, where it is activated to cis-retinoic acid, an obligatory step for RXR activation (32) . Thus, antiproteases, by interacting with CRABP, would impair the activation of retinoic acid and the downstream function of RXR-PPAR␣. In support of this proposed mechanism is a recent report describing the toxicity of isotretinoin, when coadministered with PI (34) . Concordant also are our observations that TGs, apo C-III, apo E, and the corresponding lipoparticles were effectively reduced after fenofibrate, which acts through direct activation of PPAR␣. These reductions likely reflect the effectiveness of fenofibrate, although we did not strictly control for absence of dietary change during the period of the trial.
The most dramatic changes in the lipoprotein profile on PI administration concern apo E and the Lipo B:E lipoparticles. Carr et al. (33) have also reported on the relative homology between the HIV-1 protease and the LRP, a receptor that binds apo E (10). They suggested that anti-proteases might impair the function of LRP, leading to the accumulation of remnant particles. However, as discussed above, the presence of excess apo C-III on a particle, may impair the normal interaction of apo E with receptors and, thus, cause accumulation of those apo E-containing particles. Apo E-rich The median values for lipoprotein markers, as determined above in our whole population of HIV patients, were taken as thresholds. This enabled to separate, for every parameter, two subgroups: below and above threshold. The prevalence of lipodystrophy in those two subgroups was calculated. The statistical significance of the differences between subgroups was determined by the 2 test. Thirteen patients from the RTNI ϩ PI group, presenting with severe hyperlipemia, were further administered 200 mg/day fenofibrate. After 2 months, the metabolic parameters were reevaluated. Statistical comparisons between the two groups were assessed by the Student's t test for paired assays.
a , P Ͻ 0.01;
particles may be highly atherogenic because the presence of multiple copies of apo E renders them avidily taken up by macrophages (35) . Impaired glucose tolerance and hyperinsulinism have been commonly described as side effects of PI therapy (1, 4) . In our present observations, fasting insulin was 50% higher in both groups of patients compared with controls, whereas glucose levels were significantly lower. These data suggest a ␤-cell dysfunction on prolonged antiretroviral treatment, as demonstrated previously (4) . The levels of plasma insulin that we found are rather comparable with those recently reported in HIV patients treated either with RTNI alone or with PI (36) . Nevertheless, C-peptide, an indicator of insulin secretion, was found higher in PI-treated than in PI-naive patients. Among the former, elevated C-peptide levels (Ͼ2.5 ng/mL) were associated with the highest increases in TGs, cholesterol, and apoproteins B, C-III, and E (data not shown). Thus, several elements of the metabolic syndrome are present in PI-treated patients (hyper-TG, low HDL, hyperinsulinism). It was recently demonstrated that PIs lower the expression of insulin receptors on adipocytes (37) . This may favor the release of free fatty acids from adipocyte stores and the further synthesis of TGs by the liver.
Several factors predisposing to the occurrence of LD on PI therapy have been proposed (11, 12, 20, 33) . In agreement with earlier reports, neither the viral load nor the CD4 lymphocyte counts were different between LDϩ and LDϪ patients (4, 11, 12) . Again, recent reports have questioned the precise role of PIs in the pathogenesis of LD and stressed the implication of RTNIs. For instance, lipodystrophic syndromes have been described in patients receiving only longterm nucleoside analogs, particularly Stavudine and/or Lamivudine (38, 39) . A precursor phenotype of LD was recently documented by DEXA, in patients receiving only RTNIs (36) . An interesting hypothesis is that RTNIs might be deleterious toward mitochondrial DNA, through interference with the ␥ polymerase, and cause mitochondrial dysfunction (20) . In vitro, an effect Zidovudine was demonstrated on hepatoma cells, inducing an increase in lactic acid and an inhibition of mitochondrial enzymes (40) . Analogies between the antiretroviral-triggered LD and other lipomatoses, associated with mitochondrion alterations, lends support to this hypothesis. Finally, data from observational cohorts show a strong association between the time of exposure to RTNIs and the onset of lipoatrophy (20) . However, the development of LD seems to be considerably accelerated by the addition of antiproteases (41) . A role for PPARs in the pathogenesis of LD can also be foreseen (42) . Indeed, in adipose tissue, the PPAR␥ isoform is predominantly expressed, playing a role in adipocyte differentiation, proliferation, and apoptosis (43) . In line with the hypothesis discussed above for (liver) PPAR␣, a defect in PPAR␥ activation on PIs could affect fat distribution. Moreover, a massive apoptosis of sc adipocytes could lead to enhanced flux of free fatty acids to the liver and secondary VLDL synthesis.
Looking for possible determinants of LD occurrence, and taking into consideration the duration of antiretroviral therapy, we found that a more than 30 mg/L apo C-III level was a strong predictor. This result suggests a relationship between both syndromes: dyslipemia and LD.
In conclusion, measurements of apo C-III, apo E, and the corresponding lipoparticles seem to be important in the follow-up of PI-treated patients. Prospective studies, including these markers, are needed to further explore the possible association of these markers with the development of a lipodystrophic syndrome.
